Open AccessDisease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy
Author(s) -
Samuel J. Rubin,
Tatiana Balabanis,
John Gubatan,
Aida Habtezion
Publication year - 2022
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v10.i6.1787
Subject(s) - medicine , exacerbation , inflammatory bowel disease , diarrhea , disease , malignancy , retrospective cohort study , colitis , gastroenterology
Colitis is a known potential toxicity of immune checkpoint inhibitors (ICIs). Studies evaluating the risk of disease exacerbation following ICI treatment in patients with pre-existing inflammatory bowel disease (IBD) are limited.